Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review

被引:0
|
作者
Almulhem, Maryam [1 ,2 ]
Ward, Christopher [1 ]
Haq, Iram [1 ,3 ]
Gray, Robert D. [4 ]
Brodlie, Malcolm [1 ,3 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, England
[2] King Faisal Univ, Coll Appl Med Sci, Al Hasa, Saudi Arabia
[3] Newcastle Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Paediat Resp Med, Newcastle Upon Tyne, England
[4] Univ Glasgow, Sch Infect & Immun, Glasgow, Scotland
关键词
pulmonary exacerbation; cystic fibrosis; definition; QUALITY-OF-LIFE; CHILDREN; ADULTS; TRIAL; AZITHROMYCIN; RATIONALE; FREQUENCY; OUTCOMES; DESIGN; FEV1;
D O I
10.1136/bmjresp-2024-002456
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Pulmonary exacerbations (PExs) are clinically important in people with cystic fibrosis (CF). Multiple definitions have been used for PEx, and this scoping review aimed to identify the different definitions reported in the literature and to ascertain which signs and symptoms are commonly used to define them.Methods A search was performed using Embase, MEDLINE, Cochrane Library, Scopus and CINAHL. All publications reporting clinical trials or prospective observational studies involving definitions of PEx in people with CF published in English from January 1990 to December 2022 were included. Data were then extracted for qualitative thematic analysis.Results A total of 14 039 records were identified, with 7647 titles and abstracts screened once duplicates were removed, 898 reviewed as full text and 377 meeting the inclusion criteria. Pre-existing definitions were used in 148 publications. In 75% of papers, an objective definition was used, while 25% used a subjective definition, which subcategorised into treatment-based definitions (76%) and those involving clinician judgement (24%). Objective definitions were subcategorised into three groups: those based on a combination of signs and symptoms (50%), those based on a predefined combination of signs and symptoms plus the initiation of acute treatment (47%) and scores involving different clinical features each with a specific weighting (3%). The most common signs and symptoms reported in the definitions were, in order, sputum production, cough, lung function, weight/appetite, dyspnoea, chest X-ray changes, chest sounds, fever, fatigue or lethargy and haemoptysis.Conclusion We have identified substantial variation in the definitions of PEx in people with CF reported in the literature. There is a requirement for the development of internationally agreed-upon, standardised and validated age-specific definitions. Such definitions would allow comparison between studies and effective meta-analysis to be performed and are especially important in the highly effective modulator therapy era in CF care.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Longitudinal association between medication adherence and lung health in people with cystic fibrosis
    Eakin, Michelle N.
    Bilderback, Andrew
    Boyle, Michael P.
    Mogayzel, Peter J.
    Riekert, Kristin A.
    JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (04) : 258 - 264
  • [22] Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis
    Wagener, Jeffrey S.
    Rasouliyan, Lawrence
    VanDevanter, Donald R.
    Pasta, David J.
    Regelmann, Warren E.
    Morgan, Wayne J.
    Konstan, Michael W.
    PEDIATRIC PULMONOLOGY, 2013, 48 (07) : 666 - 673
  • [23] Ventilatory Threshold and Risk of Pulmonary Exacerbations in Cystic Fibrosis
    Campos, Natalia E.
    Vendrusculo, Fernanda M.
    Perez-Ruiz, Margarita
    Donadio, Marcio V. F.
    RESPIRATORY CARE, 2023, 68 (05) : 620 - 627
  • [24] Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials
    Nikniaz, Zeinab
    Nikniaz, Leila
    Bilan, Nemat
    Somi, Mohammad Hossein
    Faramarzi, Elnaz
    WORLD JOURNAL OF PEDIATRICS, 2017, 13 (04) : 307 - 313
  • [25] Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials
    Mayer-Hamblett, Nicole
    Saiman, Lisa
    Lands, Larry C.
    Anstead, Michael
    Rosenfeld, Margaret
    Kloster, Margaret
    Fisher, Leigh
    Ratjen, Felix
    CONTEMPORARY CLINICAL TRIALS, 2013, 36 (01) : 99 - 105
  • [26] Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis
    Wagener, Jeffrey S.
    VanDevanter, Donald R.
    Konstan, Michael W.
    Pasta, David J.
    Millar, Stefanie J.
    Morgan, Wayne J.
    PEDIATRIC PULMONOLOGY, 2020, 55 (03) : 828 - 834
  • [27] Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset
    Rogers, Geraint B.
    Hoffman, Lucas R.
    Johnson, Matt W.
    Mayer-Hamblett, Nicole
    Schwarze, Juergen
    Carroll, Mary P.
    Bruce, Kenneth D.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2011, 11 (02) : 197 - 206
  • [28] Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint
    VanDevanter, D. R.
    Yegin, A.
    Morgan, W. J.
    Millar, S. J.
    Pasta, D. J.
    Konstan, M. W.
    JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (06) : 453 - 459
  • [29] Treatment of pulmonary exacerbations in cystic fibrosis
    Ng, Christabella
    Nadig, Tejaswi
    Smyth, Alan R.
    Flume, Patrick
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (06) : 679 - 684
  • [30] Manual therapies in cystic fibrosis care: a scoping review
    Sinderholm, Niklas Sposato
    Bjersa, Kristofer
    CHIROPRACTIC & MANUAL THERAPIES, 2023, 31 (01)